Oxford Nanopore Technologies (ONT.L)
Oxford Nanopore provides portable and scalable DNA and RNA sequencing technology that enables real-time, high-accuracy analysis of genetic material.
What Oxford Nanopore Technologies does
Oxford Nanopore Technologies is a biotechnology company that develops and sells nanopore-based electronic sensing technology for the analysis of DNA, RNA, and other molecules. Its platform provides real-time, scalable sequencing data suitable for scientific research across diverse fields including human genetics, cancer research, plant and animal health, and infectious disease surveillance.
Themes: genomics, DNA sequencing, precision medicine, molecular diagnostics, biotech research tools
Fundamentals
- Price£1.15 as of 2026-08-03 close
- Market capn/a company fundamentals are not available for UK-listed companies in our data
- 1-year return-42.4% 2025-08-01 close £2.00 → 2026-08-03 close £1.15
- P/En/a company fundamentals are not available for UK-listed companies in our data
- Net marginn/a company fundamentals are not available for UK-listed companies in our data
- Gross marginn/a company fundamentals are not available for UK-listed companies in our data
- ROEn/a company fundamentals are not available for UK-listed companies in our data
- Debt / equityn/a company fundamentals are not available for UK-listed companies in our data
- Revenue growth (YoY)n/a company fundamentals are not available for UK-listed companies in our data
- Revenue CAGR (3y)n/a company fundamentals are not available for UK-listed companies in our data
- Betan/a we do not track a market benchmark for UK-listed companies
Dividend: company fundamentals are not available for UK-listed companies in our data.
How Oxford Nanopore Technologies looks technically
Oxford Nanopore Technologies (ONT.L) is trading 10.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 118 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day low about 8 trading days ago. It is 48.9% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 0% of its 30-day average.
Trend
| Distance from the 200-day | -10.4% | it is trading 10.4% below its 200-day average, the long-term trend line — a long-term downtrend |
|---|---|---|
| 50-day moving average | £1.21 | its average price over the last 50 trading days — a short-term trend line — is £1.21 |
| 200-day moving average | £1.28 | its average price over the last 200 trading days — the long-term trend line — is £1.28 |
| Since the 50/200 cross | 118 sessions | its 50-day average crossed below its 200-day average about 118 trading days ago — a "death cross", a bearish long-term signal |
| Trend strength (14-day ADX) | 22.9 | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) |
Momentum
| 14-day RSI | 49.7 | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 50, neither overbought (above 70) nor oversold (below 30) |
|---|---|---|
| Since the MACD crossed zero | 3 sessions | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) |
Range
| 52-week high | £2.25 | its highest closing price over the past year (about 252 trading days) was £2.25 |
|---|---|---|
| From the 52-week high | -48.9% | it is 48.9% below its 52-week high (its highest price of the past year) |
| Above the 52-week low | +20.2% | it is 20.2% above its 52-week low (its lowest price of the past year) |
| Below the 52-week high | 48.9% | it is 48.9% below its highest point of the past year |
| Since a 20-day breakout | 8 sessions | it made a new 20-day low about 8 trading days ago |
| Since a 55-day breakout | 8 sessions | it made a new 55-day low about 8 trading days ago |
| All-time high | £7.36 | its highest closing price on record is £7.36 (set on 2021-12-02) |
| From the all-time high | -84.4% | it is 84.4% below its all-time high |
| All-time low | £0.85 | its lowest closing price on record is £0.85 (set on 2024-06-27) |
| Above the all-time low | +35.2% | it is 35.2% above its all-time low |
Volatility
| Band width vs its own 6 months | 1st percentile | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move |
|---|---|---|
| Bollinger bands (20-day, ±2σ) | £1.06 – £1.14 – £1.21 | most of its recent trading has stayed between about £1.06 and £1.21 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles |
Volume
| Volume vs its 30-day average | 0.00× | trading volume is unusually light — only about 0% of its 30-day average |
|---|
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-03. Describes past price behavior only — informational, not financial advice.
Key risks (from latest filing)
["high competition in the rapidly evolving DNA sequencing market","reliance on sustained R&D investment and technological innovation","potential for regulatory changes impacting clinical adoption of sequencing technology"]
Competitors & peers
- Illumina (ILMN)
- Pacific Biosciences (PACB)
- Thermo Fisher Scientific (TMO)
- Agilent Technologies (A)
- BGI Group
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ONT.L vs…
Frequently asked questions
What does Oxford Nanopore Technologies (ONT.L) do?
Oxford Nanopore Technologies is a biotechnology company that develops and sells nanopore-based electronic sensing technology for the analysis of DNA, RNA, and other molecules. Its platform provides real-time, scalable sequencing data suitable for scientific research across diverse fields including human genetics, cancer research, plant and animal health, and infectious disease surveillance.
Who are Oxford Nanopore Technologies's (ONT.L) competitors?
Notable peers of Oxford Nanopore Technologies (ONT.L) include Illumina, Pacific Biosciences, Thermo Fisher Scientific, Agilent Technologies and BGI Group. This peer set is informational only — not financial advice.
Is Oxford Nanopore Technologies (ONT.L) overbought or oversold right now?
Oxford Nanopore Technologies (ONT.L) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 50, in the neutral middle (as of 2026-08-03). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ONT.L come from?
Fundamentals and prices come from market data. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from market data, shown with their as-of date.